Q-omics provides the consensus-scored SEMA3B profile across patient tissues and cancer cell-line models. SEMA3B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEMA3B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SEMA3B protein abundance shows 21,103 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where SEMA3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA3B survival associations across molecular data types. SEMA3B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA3B RNA expression–survival associations across cancer types. High SEMA3B expression shows unfavorable associations in LUSC, THCA and LGG, but favorable associations in UVM, BRCA and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SEMA3B RNA expression.
This table summarizes SEMA3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEMA3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA3B shows lower tumor expression in KIRC, BLCA, KICH, LUAD and LUSC and higher tumor expression in LIHC. The KIRC box plot shows higher SEMA3B RNA expression in normal versus tumor tissue (log2 FC = −2.242, t-test p < 0.001).
This table shows molecular features associated with SEMA3B in patient tissues and cancer cell lines. In patient samples, SEMA3B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
